These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 31426938)
1. Important Considerations in Modeling the Cost-Effectiveness for the First Food and Drug Administration-Approved Gene Therapy and Implications for Future One-Time Therapies. Buessing M; O'Connell T; Johnson S; Pitluck S; Ciulla TA Value Health; 2019 Aug; 22(8):970-971. PubMed ID: 31426938 [No Abstract] [Full Text] [Related]
2. Regulatory and Economic Considerations of Retinal Drugs. Shah AR; Williams GA Dev Ophthalmol; 2016; 55():376-80. PubMed ID: 26502165 [TBL] [Abstract][Full Text] [Related]
3. Must Sky-High Prices 'Come on Down' Before the Price Is Right? Kirkner RM Manag Care; 2018 Jul; 27(7):16-19. PubMed ID: 29989894 [TBL] [Abstract][Full Text] [Related]
5. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis. D'Souza LS; Payette MJ J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851 [TBL] [Abstract][Full Text] [Related]
6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information. Morris LA Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603 [No Abstract] [Full Text] [Related]
7. Estimated cost efficacy of U.S. Food and Drug Administration-approved treatments for acne. Tassavor M; Payette MJ Dermatol Ther; 2019 Jan; 32(1):e12765. PubMed ID: 30288869 [No Abstract] [Full Text] [Related]
8. The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature. Becker R; Dembek C; White LA; Garrison LP Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):775-93. PubMed ID: 23252359 [TBL] [Abstract][Full Text] [Related]
9. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. Neumann PJ J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371 [TBL] [Abstract][Full Text] [Related]
10. Rollout of high-priced cell and gene therapies forces payer rethink. Senior M Nat Biotechnol; 2018 Apr; 36(4):291-292. PubMed ID: 29621215 [No Abstract] [Full Text] [Related]
11. A Time-Trend Economic Analysis of Cancer Drug Trials. Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135 [TBL] [Abstract][Full Text] [Related]
12. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016. J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395 [No Abstract] [Full Text] [Related]
14. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. Mailankody S; Prasad V JAMA Oncol; 2015 Jul; 1(4):539-40. PubMed ID: 26181265 [No Abstract] [Full Text] [Related]
15. The FDA and regulation of cost-effectiveness claims. Neumann PJ; Zinner DE; Paltiel AD Health Aff (Millwood); 1996; 15(3):54-71. PubMed ID: 8854508 [TBL] [Abstract][Full Text] [Related]
16. Biotechnology: will it break the health care bank? McGivney WT Physician Exec; 1992; 18(5):35-6. PubMed ID: 10121675 [TBL] [Abstract][Full Text] [Related]
17. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective. Temple R Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602 [No Abstract] [Full Text] [Related]
19. Pharmacoeconomic analyses make way into oncology. Amber D J Natl Cancer Inst; 2000 Aug; 92(15):1204-5. PubMed ID: 10922402 [No Abstract] [Full Text] [Related]
20. Reducing the risk of fractures--the options narrow for cost-effective therapeutic alternatives. Curtiss FR J Manag Care Pharm; 2004; 10(2):168-79. PubMed ID: 15032568 [No Abstract] [Full Text] [Related] [Next] [New Search]